Loading...
Company2018-05-28T16:52:07+00:00

WHAT WE DO

Biohope Ltd. is a start-up biomedical company focused in the research and development of novel solutions, to personalize and optimize the clinical management of chronic inflammation in patients under treatment with immunosuppressive and/or immunomodulatory therapies.

To develop innovative, honest, simple, and viable science to help improve human lives.

MISSION

Biohope strives to be a leader in the generation of scientifically and socioeconomically sustainable innovative solutions in the field of immunologically based diseases.

VISION

Creative innovation –  Quality work –  Commitment to the project and to society Scientific, economic, and social transparency – Free expression of talent

VALUES

CORE GOALS

To facilitate medical doctors to personalize and optimize the medical treatment in their patients with organ transplantation and rheumatoid arthritis.

To market IMMUNOBIOGRAM as a simple & highly scalable technology easy to use.

Start worldwide sales from 2Q2020

Create a highly motivating and creative company environment.

WE ARE ON PLAN

Biohope is a fast-growing company that has achieved significant goals in less than three years of existence, and we keep on moving!

INMUNOBIOGRAM R+D Plan

RENAL TRANSPLANTATION. Biohope has successfully finished a National Study (BH-Pilot). We work with 8 top-class Transplant Units of 4 EU countries and MGH (Harvard School of Medicine) in an International Multicenter clinical Study

RHEUMATOID ARTHRITIS. Biohope is initiating a national study to adapt the Inmunobiogram® technology to this new indication.

IMMUNOBIOGRAM Patents

We have applied for several EU patents and PCT for the technology under our bioassay IMMUNOBIOGRAM, and we expect the project will deliver further industrial property

ORGANIZATIONS

The National Transplant Organization of Spain, the most renowed transplant organization in Europe, supported this project to be scaled up to European scope.  We also have been offered support to the project from 5 Public Administration entities.

INMUNOBIOGRAM-Regulatory and Product Development

Functional prototype and user interface ongoing. Quality Assurance System (ISO 13485) in progress to obtaine CE Mark. FDA aproval follows 510 K patterway.